Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Enzymaster (Ningbo) Bio-Engineering Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, Paul J Holland, who is the busiest examiner with 1 pending action. The matter is within a distinct art unit, which means the company's current prosecution outcomes rely on a single examiner's evaluation.
This highly concentrated profile means that the practitioner only needs to manage a distinct examiner and a single art unit. There is no need to coordinate between different technical groups or account for varying examiner preferences. The strategy for the 1 pending office action can be specifically designed to meet the expectations of Paul J Holland in the biotechnology field.
With only 1 pending action, the company's immediate patent success is tied to this single proceeding. The legal team should focus on the specific technical standards of the art unit involved. By providing a targeted and precise response to the concerns of the 1 examiner, the practitioner can efficiently move the company's intellectual property toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711814 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | HOLLAND, PAUL J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711814 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | HOLLAND, PAUL J | 1656 | §112 | Non-Final OA | — | Pending | May 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial